AlphaCrest Capital Management LLC Invests $300,000 in Illumina, Inc. (ILMN)

AlphaCrest Capital Management LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,000 shares of the life sciences company’s stock, valued at approximately $300,000.

Several other large investors also recently bought and sold shares of ILMN. Oregon Public Employees Retirement Fund grew its holdings in shares of Illumina by 66,581.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock valued at $35,000 after purchasing an additional 10,546,495 shares during the last quarter. Capital International Investors bought a new position in shares of Illumina during the third quarter valued at approximately $1,482,837,000. Canada Pension Plan Investment Board grew its holdings in shares of Illumina by 272.2% during the third quarter. Canada Pension Plan Investment Board now owns 1,023,452 shares of the life sciences company’s stock valued at $375,668,000 after purchasing an additional 748,500 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Illumina by 13.5% during the fourth quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock valued at $1,643,486,000 after purchasing an additional 653,348 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Illumina by 362.9% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 433,566 shares of the life sciences company’s stock valued at $130,039,000 after purchasing an additional 339,908 shares during the last quarter. 90.32% of the stock is owned by institutional investors.

Get Illumina alerts:

In related news, SVP Charles Dadswell sold 1,220 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $313.93, for a total value of $382,994.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction that occurred on Wednesday, December 12th. The stock was sold at an average price of $334.13, for a total value of $1,102,629.00. Following the completion of the transaction, the director now directly owns 374,859 shares of the company’s stock, valued at $125,251,637.67. The disclosure for this sale can be found here. Insiders sold a total of 39,470 shares of company stock valued at $11,810,716 over the last three months. Corporate insiders own 0.54% of the company’s stock.

Several equities analysts have recently commented on the company. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $347.00 target price for the company in a report on Friday, January 11th. Morgan Stanley lowered their target price on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a report on Monday, January 7th. Deutsche Bank lowered Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a report on Friday, January 25th. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and upped their target price for the company from $340.00 to $370.00 in a report on Thursday, January 3rd. Finally, BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a report on Wednesday, February 13th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $345.82.

Shares of ILMN stock opened at $292.06 on Friday. Illumina, Inc. has a 12-month low of $225.82 and a 12-month high of $372.61. The company has a market capitalization of $44.26 billion, a P/E ratio of 52.63, a price-to-earnings-growth ratio of 2.14 and a beta of 1.20. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.49 and a quick ratio of 2.27.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Illumina had a return on equity of 24.51% and a net margin of 24.79%. The business had revenue of $867.00 million during the quarter, compared to the consensus estimate of $865.33 million. During the same period last year, the company earned $1.44 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Equities research analysts forecast that Illumina, Inc. will post 6.53 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AlphaCrest Capital Management LLC Invests $300,000 in Illumina, Inc. (ILMN)” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4205306/alphacrest-capital-management-llc-invests-300000-in-illumina-inc-ilmn.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: How to find the components of the quick ratio

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).